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From January 1, 1995, to December 31, 1997, we reviewed records of all New York City patients who had
multidrug-resistant tuberculosis (MDRTB); we performed insertion sequence (IS) 6110-based DNA geno-
typing on the isolates. Secondary genotyping was performed for low IS6110 copy band strains. Patients
with identical DNA pattern strains were considered clustered. From 1995 through 1997, MDRTB was diag-
nosed in 241 patients; 217 (90%) had no prior treatment history, and 166 (68.9%) were born in the United
States or Puerto Rico. Compared with non-MDRTB patients, MDRTB patients were more likely to be born
in the United States, have HIV infection, and work in health care. Genotyping results were available for 234
patients; 153 (65.4%) were clustered, 126 (82.3%) of them in eight clusters of >4 patients. Epidemiologic
links were identified for 30 (12.8%) patients; most had been exposed to patients diagnosed before the
study period. These strains were likely transmitted in the early 1990s when MDRTB outbreaks and tuber-
culosis transmission were widespread in New York. 
idespread transmission of multidrug-resistant Mycobac-
terium tuberculosis (MDRTB) strains occurred during
the epidemic of the 1980s and early 1990s in New York City.
Outbreaks were identified in many New York City hospitals
and subsequently in New York State correctional facilities.
Many of these outbreaks were associated with one strain
(known as the "W" strain of TB) that was resistant to isoniazid,
rifampin, ethambutol, and streptomycin and usually to kana-
mycin (1–5). However, other multidrug-resistant (MDR)
strains were associated with outbreaks and nosocomial trans-
mission during these years (6–8). Previous molecular epidemi-
ology surveys in New York City showed that MDRTB was
associated with clustered M. tuberculosis strains, which sug-
gests recent transmission of the organism (9–11). The inci-
dence of tuberculosis (TB) and MDRTB has been decreasing
rapidly in New York City since 1992, when an enhanced
Tuberculosis Control Program was implemented. The number
of TB cases decreased 21.5% by 1994 (from 3,811 in 1992 to
2,995 in 1994), and MDRTB cases decreased 60% (from 441
to 176) (12,13). Since 1994, no outbreaks of MDRTB have
been documented in the city.
To better understand the epidemiology of MDRTB, the
New York City Tuberculosis Control Program began DNA
genotyping of MDRTB strains from new cases in 1995. The
objectives were to provide descriptive molecular epidemiol-
ogy of MDRTB cases in the city during 1995–1997 and to
identify predominant MDR strains present during these years,
as well as the extent and risk factors for clustering among
these cases.
Methods
Patient Selection
All patients with MDRTB (M. tuberculosis isolate resistant
to at least isoniazid and rifampin) confirmed as TB cases from
January 1, 1995, to December 31, 1997, in New York City
were included. Demographic and clinical data were obtained
from the New York City Tuberculosis Case Registry. The Reg-
istry’s data were obtained from patient interviews and medical
record reviews at the treatment or residential facilities by
trained case managers using standardized data collection
instruments and from contact investigations for each pulmo-
nary case. 
Susceptibility results were reviewed for the following TB
treatment drugs: isoniazid, rifampin, pyrazinamide, ethambu-
tol, streptomycin, and rifabutin (first-line drugs) and fluoro-
quinolone (usually ciprofloxacin or oflaxacin), kanamycin or
amikacin, capreomycin, ethionamide, para-aminosalicylic
acid, and cycloserine (second-line drugs). Susceptibility tests
were done by Bactec radiometric method (Becton Dickinson
and Co., Sparks, NY) for first-line drugs, except rifabutin (14),
for most isolates and with standard proportion method with
Middlebrook 7H10 media for both first- and second-line drugs
for all isolates (15). Most of these tests were conducted at two
reference laboratories, the New York City Department of
Health and the New York State Department of Health, Wad-
sworth Center.
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As part of routine surveillance, we reviewed the clinical
histories of all pulmonary TB patients who had a negative acid-
fast bacilli smear and only one positive M. tuberculosis isolate
from a respiratory source. This review was to determine the
accuracy of the culture result and to rule out laboratory error. If
laboratory error was suspected for other types of specimens,
clinical and laboratory data for patients were reviewed. Labora-
tory error was defined as a false-positive M. tuberculosis cul-
ture result that was caused by specimen mislabeling or
laboratory cross-contamination, as evaluated by a described
method (10). These patients were not counted as having veri-
fied cases of TB and were excluded from the analysis.
Definitions
Patients were defined as having had prior treatment for TB
if 1) drug-susceptible M. tuberculosis isolates were identified
before the drug-resistant isolates that qualified the patients for
this study; 2) they had documentation of previous TB disease
or treatment; or 3) they had received >30 days of treatment
with anti-TB drugs before collection of the specimen that grew
MDR M. tuberculosis. 
Patients were considered HIV seropositive when a positive
HIV antibody test result was documented in the medical
record or when AIDS was diagnosed before the TB diagnosis.
The MDRTB diagnosis date was defined as the collection date
of the first specimen from which an MDR M. tuberculosis iso-
late was cultured. Homelessness was defined as being in a
public or private shelter or having no address at the time of the
MDRTB diagnosis. Information about injection drug use
within the 12 months before diagnosis was elicited from direct
patient interviews and medical record reviews.
Epidemiologic Investigations
Trained case managers obtained information about sus-
pected and confirmed nosocomial and community exposure
from patient interviews, contact investigations, and medical
record reviews at the treatment or residential facilities. Proba-
ble nosocomial transmission was considered if the newly
infected patient was in the same section of an institution as
another patient who had an identical M. tuberculosis strain and
was infectious (i.e., the patient had a positive culture from a
respiratory site) at least 30 days before disease onset in the
newly infected patient. 
Community transmission was considered probable if either
of the following occurred: 1) A patient was exposed to another
patient who had the identical M. tuberculosis strain and was
infectious (i.e., had a positive culture from a respiratory site) at
least 30 days before disease onset in the subsequent patient. The
exposure would have occurred in a home, single-room occu-
pancy hotel, homeless shelter, or another noninstitutional set-
ting. 2) The patient named another patient as a contact whose M.
tuberculosis isolate had the same DNA pattern or who had
MDRTB, but DNA genotyping result was not available.
Transmission could have been from a patient whose condi-
tion was diagnosed before the study period. If evidence of
nosocomial or community transmission was found, patients
had an epidemiologic link. The source patient was not consid-
ered to have an epidemiologic link.
During 1995 through 1996, nosocomial transmission was
suspected at a hospital where the same MDR strain (i.e., iden-
tical insertion sequence [IS] 6110 band patterns) was found in
six patients. Hospital floor, ward, and bed information and
computerized outpatient clinic records from 1990 to 1996
were analyzed for temporal and spatial overlap among these
patients. Medical records were reviewed for patient breaches
of isolation protocol during hospitalization. Additional social
and demographic information was collected through question-
naires. Specifically, patients were asked with whom and where
they spent considerable time, and names of additional social
contacts were requested. Patients were asked where and how
they thought they had been exposed to TB.
IS6110 DNA Genotyping and Other Molecular Studies
From 1995 through 1997, one M. tuberculosis isolate from
each patient with MDRTB in New York City was sent to the
Public Health Research Institute Tuberculosis Center, where
DNA fingerprint analysis, based on IS6110 Southern blot
hybridization pattern, was performed by using a standardized
protocol (16). The Southern hybridization patterns were com-
pared on a Sun Sparc5 Workstation (Sun MicroSystems, Santa
Clara, CA), using Bio Image Whole Band Analyzer software
version 3.4 (Bio Image, Ann Arbor, MI). Previously described
methods were used to classify isolates (17). IS6110 banding
patterns, which were similar to a parent strain but differed by
one or two hybridization bands, were denoted by the addition
of a number to the cluster letter (e.g., W, W1, P, or P1).
Secondary genotyping was performed by using spacer oli-
gonucleotide typing (spoligotyping) and DNA sequencing of
target gene regions that confer drug resistance. Spoligotyping
and DNA sequencing of target gene regions used previously
described methods (18–21).
If M. tuberculosis isolates had identical IS6110 band pat-
terns, they were considered clustered. However, identical
IS6110 patterns with less than six bands were not considered
clustered, unless secondary DNA analysis confirmed a match,
as noted in the results.
Data Analysis
To examine how MDR patients differed from non-MDR
patients, study subjects were compared to persons who had
culture-positive TB diagnosed during the same period but
were not included in this study. Descriptive analysis was per-
formed for all study patients according to drug resistance pat-
terns, DNA patterns, prior TB treatment, social and
demographic variables, and evidence of nosocomial and com-
munity transmission. The Wilcoxon rank-sum test was used to
compare medians of continuous variables, and the Pearson chi-
square test was used to compare categorical data. Uncondi-
tional logistic regression was used to assess crude odds ratios
and 95% confidence intervals for the association betweenTUBERCULOSIS GENOTYPING NETWORK
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potential risk factors and clustering. Statistical Analysis Sys-
tem Software (Release 8.01, SAS Institute, Inc., Cary, NC)
was used for all data analyses. Statistical significance was set
at a two-sided 5% level.
Results
From 1995 through 1997, a total of 6,228 cases of TB were
confirmed in New York City. Cultures from 5,136 (82.4%)
persons were positive for M. tuberculosis. Of these, suscepti-
bility results were available for 4,955 (96.5%); 241 (4.9%)
persons had MDRTB. Findings of MDR for 11 additional iso-
lates resulted from laboratory error (10 sputum and 1 urogeni-
tal); they were excluded from further analyses. The 241
patients made up 4.4% (106 of 2,445), 3.9% (81 of 2,053), and
3.1% (54 of 1,730) of all verified patients who had TB from
1995, 1996, and 1997, respectively. Table 1 presents a compar-
ison of the demographic characteristics of these patients to
those of culture-positive non-MDRTB patients from the same
time period in New York City for whom drug susceptibility
results were available. Compared with patients with culture-
positive non-MDRTB during the same period, MDR patients
were more likely to be born in the United States, have HIV
infection, and be health-care workers, homeless, and injection
drug users. MDR patients were more likely to have respiratory
specimens positive for acid-fast bacilli and were less likely to
be Asian. By further stratification, none of Asian MDRTB
patients were born in the United States, and 68.7% of U.S.-
born MDRTB patients were HIV infected.
Strains were resistant to a median number of 6 drugs
(range 2–10). Eight (3.3%) patients had strains of M. tubercu-
losis that were resistant to isoniazid and rifampin only, and 146
(60.6%) had isolates that were also resistant to one or more
second-line anti-TB drugs. Most of these strains were also
resistant to rifabutin. Twenty-four (10%) patients had received
prior treatment for TB. Compared with patients who had no
prior treatment, patients who had received such treatment were
significantly older (median age 46 years vs. 41 years, p=0.010)
and had less drug resistance (median 5 drugs versus 6,
p=0.042). Patients with prior treatment were less likely to be
born in the United States (45.8% vs. 71.4%, p=0.001) and
were less likely to be HIV infected (33.3% vs. 55.3%,
p=0.041). Patients who had received prior treatment did not
differ from those who had no prior treatment according to gen-
der, race or ethnicity, occupation, and histories of alcohol or
drug abuse and homelessness.
DNA Genotyping Analysis
Of 241 MDR patients, 234 (97%) had IS6110 fingerprint
patterns. Ninety-two different patterns were identified (band
range 2–22). Thirty-six (15.4%) of 234 isolates had patterns
with five or fewer IS6110 bands. Five were in one cluster, the
C strain,  and all had the same spoligotype
(700036777760731). Two were clustered as a four-band strain
with the same spoligotypes, and three other strains had unique
genotypes. Twenty-six strains had an identical two-band
IS6110 pattern designated as H; 25 of the 26 were resistant to
pyrazinamide. All 17 with available results had identical spoli-
gotypes (777776777760601); 18 of the 20 strains that were
tested had identical pncA genotype (Nt70; G deletion). One
pyrazinamide-susceptible strain had the wild-type pncA geno-
type, and one resistant strain had a different pncA genotype
(139; GTG>GCG, Val>Ala). On the basis of the results, 18 of
the 26 H strains were considered clustered. Thus, 25 of the 36
isolates with low IS6110 copies were considered clustered.
Of 234 patients with DNA results, 153 (65.4%) were
grouped into 19 clusters: 6 clusters with 2 cases each; 5 clus-
ters with 3 cases each; and 8 different clusters with 4, 5, 6, 7,
13, 14, 18, and 59 cases each. The eight clusters had 126
(52.2%) of 241 MDRTB patients from the study period. Table
2 shows the distribution of these eight strains during 1995
Table 1. Comparison of social and demographic characteristics of mul-
tidrug-resistant (MDR) tuberculosis patients and non-multidrug-resis-
tant tuberculosis patients, New York City, 1995–1997
Characteristic
MDR (n=241)
Non-MDR 
(n=4,714)
p value No. % No. %
Yr of diagnosis
1995 106 44.0 1,816 38.5 0.0898
1996 81 33.6 1,586 33.6 0.9912
1997 54 22.4 1,312 27.8 0.0660
Median age (range), yrs 41 (5–85) 41 (0–100) 0.3071
Male sex 147 61.0 3,020 64.1 0.3333
U.S.-born 166 68.9 2,483 52.7 <0.001
HIV serostatus
Positive 128 53.1 1,478 31.4 <0.001
Negative 75 31.2 1,759 37.3 0.0521
Unknown 38 15.8 1,477 31.3 <0.001
Race/ethnicity
Asian 24 10.0 817 17.3 0.0029
Hispanic 75 31.1 1,266 26.9 0.1461
Black non-Hispanic 105 43.6 2,089 44.3 0.8200
White non-Hispanic 37 15.4 542 11.5 0.0692
Health-care worker 15 6.2 109 2.3 0.0001
Homeless 28 11.6 344 7.3 0.0130
Injection drug user 33 13.7 275 5.8 <0.001
Disease site
Pulmonary only 176 73.0 3,397 72.1 0.7440
Extra-pulmonary only 35 14.5 894 19.0 0.0848
Pulmonary + extra-pulmonary  30 12.5 423 9.0 0.0679
Specimen AFB smear-positivea 141 68.5 2,129 55.7 0.0003
Cavitary lesion(s)b 47 22.8 740 19.4 0.2247
aRespiratory specimen during the 30 days after initial specimen for bacteriologic test 
was taken. Excludes those who had only extrapulmonary disease.
bExcludes those with extrapulmonary disease only.Emerging Infectious Diseases  •  Vol. 8, No. 11, November 2002 1233
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through 1997 with social, demographic, and epidemiologic
link information. Figure 1 shows the geographic distribution,
and Figure 2 shows the IS6110 patterns of these eight strains.
Epidemiologic links were identified for 30 (12.8%) of the
234 patients with genotyping results; most had been exposed
to patients diagnosed before the study period. Twenty-five
(19.8%) of 153 patients clustered by DNA genotyping were
epidemiologically linked; 18 (72%) had probable community
transmission, and 7 (28%) had probable nosocomial transmis-
sion. All nosocomial links were to patients whose conditions
were diagnosed before the study period. Seven community
transmission links were to patients from the study period, and
11 were to patients whose diseases were diagnosed before the
study period. Epidemiologic links of community transmission
were identified for 5 (6.2%) of 81 nonclustered patients; all
were links to persons whose conditions were diagnosed before
the study period. Of the 23 community links, 3 were to house-
hold members, 4 to nonhousehold relatives, and 7 to friends.
One was linked to another case in a single-room occupancy
hotel; seven were linked in a crack den, and one had an
unknown exposure site.
Table 3 shows a comparison of patients clustered by DNA
analysis to those nonclustered according to various demo-
graphic and clinical characteristics. Factors significantly asso-
ciated with clustering were HIV infection and birth in the
United States. There was no difference in proportion clustered
by year. Patients with histories of prior treatment and Asian
patients were significantly less likely (odds ratio [OR] = 0.40,
95% confidence interval [CI] = 0.17 to 0.98 and OR=0.18,
95% CI-0.06 to 0.53, respectively) to be in a cluster. Patients
in clusters were 3 times more likely to have epidemiologic
links than those not in clusters. In a subanalysis that included
only non–U.S.-born patients who had a known date of entry to
the United States, clustering was significantly associated
Table 2. Social and demographic characteristics of patients in predominantly multidrug-resistant tuberculosis clusters, New York City, 1995–1997
Characteristics
Clustered strain (n=234) Unique 
W W1 H AB P AU C P1 Other RFLPa
No. of patients 59 7 18 14 13 6 5 4 27 81
No. of bands 18 19 2 11 11 10 3 11 4–18 2–22
Known epidemiologic links
Nosocomial 6 1 0 0 0 0 0 0 0 0
Community 4 1 2 7 1 2 0 0 1 5
Age (median, in yrs) 41 41 37 42 43 40 37 37 41 42
Male 41 3 7 7 7 4 4 3 17 49
Race/ethnicity 
Asian 2 1 1 0 1 0 1 0 0 16
Hispanic 18 2 10 1 3 1 3 2 9 24
Black, non-Hispanic 25 1 6 12 9 1 1 2 15 31
White, non-Hispanic 14 3 1 1 0 4 0 0 3 10
U.S.-born 46 4 15 13 10 5 3 3 21 42
HIV positive  42 1 14 10 4 4 3 1 17 29
History of— 
Homelessness 6 0 1 8 3 0 2 0 2 5
Alcohol abuse 11 1 1 3 4 0 0 0 5 9
Injection drug use 9 0 2 6 0 1 0 1 5 8
Prior tuberculosis treatment 0 0 1 0 1 1 2 0 5 12
Health-care worker  4 3 1 0 1 0 1 0 2 2
Borough of residence 
Manhattan 23 1 8 4 1 1 3 0 10 19
Bronx 17 0 4 0 0 0 1 0 2 8
Brooklyn 72 5 1 09 5 14 1 1 3 0
Queens 12 4 1 0 3 0 0 0 4 23
Staten Island 00 0 0 0 0 00 0 1
aRFLP, restriction fragment length polymorphism.TUBERCULOSIS GENOTYPING NETWORK
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(OR=1.09, 95% CI=1.02, l.16; p=0.01) with longer time of
residence in the United States.
Epidemiology of Predominant MDR Strains
Fourteen patients in this study had an 11-band strain (AB).
Six of these patients were diagnosed at a single medical facil-
ity in Brooklyn, New York. At the time of diagnosis, five of
these persons reported a home address in the same health dis-
trict as the medical facility. Although two patients were hospi-
talized at the medical facility when transmission could have
occurred, hospital inpatient and outpatient records showed that
nosocomial transmission was unlikely because of the room
locations and documented adherence to isolation protocol.
Our study showed the following characteristics for patients
in the AB cluster: 92.9% were born in the United States,
71.4% were infected with HIV, 85.7% were non-Hispanic
black, 42.8% used injection drugs, and 100% had no prior
treatment for TB. These patients reported home addresses
from only two of five boroughs in New York City, 10 (71.4%)
in Brooklyn and 4 (28.6%) in Manhattan. However, 57% were
homeless. Five patients agreed to additional interviews; six
patients had died, and three patients could not be located. On
the basis of the additional interviews and available data from
initial interviews, 7 of these 14 patients had community trans-
mission links. Two of these links were found through standard
contact investigations, and five were disclosed by the addi-
tional patient interviews. Three patients had close contacts
with two patients who had the AB strain in 1992; four fre-
quented the same crack den in the neighborhood of the medi-
cal facility before their TB diagnosis. The remaining seven
patients had no history of contact with persons who had the
AB strain.
The largest cluster was from the W strain—59 patients rep-
resenting almost 25% of the 241 MDRTB patients in the 3
years. This strain caused a well-documented multi-institutional
outbreak in New York City from 1990 through 1993 (1–5).
Strain W1, which was isolated in seven patients, is a variant of
the W strain. It has an additional IS6110 copy and is part of the
W strain outbreak (4,5). Forty percent (12 of 30) of the epide-
miologic links in this cohort were to patients with these two
strains. Seven (46.7%) of the 15 health-care workers had either
the W strain (4 cases) or the W1 strain (3 cases). However, epi-
Figure 1. Geographic distribution of patients in major multidrug-resistant
tuberculosis clusters, New York City, 1995–1997.
Figure 2. Insertion sequence (IS) 6110 Southern blot hybridization pat-
terns for major multidrug-resistant Mycobacterium tuberculosis strains,
New York City, 1995–1997. STD, standard.Emerging Infectious Diseases  •  Vol. 8, No. 11, November 2002 1235
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demiologic links for nosocomial transmission were found for
only two of the seven. Patients with this strain were identified
from four of the city’s five boroughs. The epidemiology of
these clusters has been described in greater detail after the
institutional outbreaks (22).
The only difference between the P and P1 strains is that the
P1 strain has an additional band. Both strains have been noso-
comially transmitted in one institution in New York City (7).
Nine of the 13 patients with the P strain and all 4 with the P1
strain were living in the same borough as the institution where
this outbreak was identified. However, epidemiologic links
were identified for only one patient. Patients in these clusters
were much less likely to be HIV infected than the other clus-
tered patients (29% vs. 67%, p=0.002).
The H strain, the other major cluster, was also associated
with a nosocomial outbreak in an institution in New York City
(8). During the study period, patients with this strain were
identified from all the city’s boroughs. Two patients with this
strain had epidemiologic links.
Discussion
During the 3-year period, 241 (3.9%) of all 6,228 TB cases
in New York City and 241 (4.9%) of all 4,995 M. tuberculosis
culture-positive patients with susceptibility had MDR strains.
MDRTB patients were more likely to have acid-fast bacilli vis-
ible on microscopic examination of respiratory specimens and
thus were more infectious. MDRTB was more common in
patients who were born in the United States, HIV infected,
non-Asian, or health-care workers. The finding of greater
prevalence of HIV infection in MDRTB patients compared
with non-MDRTB patients is likely due to several reasons.
The initial outbreaks during which these strains were transmit-
Table 3. Risk factors associated with clustering of multidrug-resistant tuberculosis cases, New York City, 1995–1997 (n=234)a
Characteristic
Clustered (n=153) Nonclustered (n=81) Crude
No. (%) No. (%) OR 95% CI
Median age in yr (range) 41 (5–85) 42 (22–77) 0.99 0.98, 1.02
Male sex 93 (60.8) 49 (60.5) 1.01 0.58, 1.76
U.S.-born 120 (79.0) 42 (51.9) 3.48 1.94, 6.25
Median years of residence in United Statesb 12 (0–47) 6.5 (0–24) 1.09 1.02, 1.16
HIV serostatus
Positive 96 (62.8) 29 (35.8) 2.81 1.52, 5.22
Negative 40 (26.1) 34 (42.0) 1.00  
Unknown 17 (11.1) 18 (22.2) 0.80 0.36, 1.80
Race/ethnicity
Asian 6 (3.9) 16 (19.8) 0.18 0.06, 0.53
Hispanic 49 (32.0) 24 (29.6) 1.00
Black non-Hispanic 72 (47.1) 31 (38.3) 1.14 0.60, 2.17
White non-Hispanic 26 (17.0) 10 (12.4) 1.27 0.53, 3.06
Health-care worker 12 (7.8) 2 (2.5) 3.36 0.73, 15.40
Homeless 22 (14.4) 5 (6.2) 2.55 0.92, 7.02
Injection drug usec 24 (15.7) 8 (9.9) 1.70 0.73, 3.97
Prior treatment history 10 (6.5) 12 (14.8) 0.40 0.17, 0.98
Having epidemiologic linkd 
Nosocomial 7 (4.6) 0 (0) 2.97 1.02, 9.26
Community 18 (11.8) 5 (11.1)
No link 128 (83.7) 76 (88.9) 1.00   
Year of diagnosis
1995 69 (45.1) 32 (39.5) 1.00
1996 54 (35.3) 27 (33.3) 0.93 0.47, 1.81
1997 30 (19.6) 22 (27.2) 0.63 0.30, 1.34 
aOR, odds ratio; CI, confidence interval.
bExcludes non-U.S.-born patients.
cInjection drug use within 12 months before diagnosis.
dCompared epidemiologic link with no epidemiologic link.TUBERCULOSIS GENOTYPING NETWORK
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ted mostly involved HIV-infected persons (1–8). A large num-
ber of HIV-infected patients were likely infected in those
outbreaks. HIV-infected patients progress from infection to
disease at a much higher rate than non–HIV-infected persons. 
Most patients in this study had primary MDRTB caused by
a few strains. The proportion of patients clustered in this
cohort is much higher than in previously reported New York
City patients. Few demographic and clinical characteristics
were associated with clustering. According to previous city-
wide surveys of all patients who had cultures that were posi-
tive for TB, the proportions of clustered patients who had TB
were 37% in 1991 and 32.4% in 1994 (10,11). Another investi-
gation from one hospital in the city found similar results for
patients during 1989–1991 (9). A more recent survey from
1997 in New York City found that, for persons born in the
United States, the proportion clustered had not decreased (23).
In all these surveys, MDRTB was associated with clustering in
multivariate analyses. The higher proportion of MDRTB clus-
tering seen in this study cannot be explained by the exclusion
of low-band patients in previous citywide surveys. When we
exclude low-band patients from our analysis, we still have a
similar proportion of clustering (128 [64.6%] of 198 isolates
with less than five bands). Our proportion of MDRTB cluster-
ing is also higher than that reported from other U.S. cities and
other industrialized countries, where approximately 18% to
49% of clustering has been observed (24–28). However, few
patients in these studies had MDRTB. The inclusion of
MDRTB patients only in this study may have contributed to
this difference. A study conducted during 1995 to 1997 by
Moro et al. in Italy showed 74.2% clustering among MDRTB
patients, compared with 39.3% among non-MDR cases (29).
Our study reiterates that a few, highly resistant strains were
transmitted widely in New York City during the late 1980s and
early 1990s.
Strains W, W1, P, P1, and H were transmitted in the early
1990s during the period of MDRTB outbreaks in New York
City because five of the eight major clustered strains were
associated with hospital outbreaks during that time (1–8). Few
patients in this cohort had epidemiologic links, but most of
these links were to patients whose diseases were diagnosed
before the study period. Most health-care workers (10 of 14
with DNA results) had one of the known outbreak strains, but
only 2 could be linked to facilities where nosocomial transmis-
sion occurred.
In addition to the nosocomially transmitted strains, we
identified a large cluster that may have been transmitted in a
community of persons who were HIV infected, homeless, and
drug users. Before this study period, at least 14 additional
MDRTB patients with this strain had been identified and con-
firmed by genotyping from 1989 through 1994. Six of these
patients were from the same borough, and four were from the
same health district as many of the patients in 1995–1997.
This strain was transmitted over many years among drug users
who were frequenting crack dens in the same neighborhood.
Since many of these venues were closed in the late 1990s, this
social group was disrupted, and transmission was interrupted.
The AB strain has been found in only two new patients during
1998–2001, one in 1998 and the other in 2001. The patient
from 2001 had epidemiologic links to a patient from 1995.
Five patients had the C strain, which has three IS6110 cop-
ies. This M. tuberculosis strain is the most common in the city.
Most of the C strains in the city share the same spoligotype
and pTBN12-based RFLP pattern and are clonal (30, New
York City Department of Health and Public Health Research
Institute, unpub. data). Most of the C strains have been drug-
susceptible; however, we identified C strains with varying
drug-resistant patterns, occasionally in clusters (30, New York
City Department of Health and Public Health Research Insti-
tute, unpub. data). The MDR strains in this period appear to be
a recent cluster, or each may have acquired drug resistance
separately.
MDRTB continues to decline in New York City at a rapid
rate, with only 38, 31, and 25 new cases identified in 1998,
1999, and 2000, respectively (31). However, most of the major
strains found in this investigation continued to be identified in
new MDRTB patients in New York City from 1998 through
2001 (New York City Department of Health and Public Health
Research Institute, unpub. data). Most nonclustered patients
had primary drug-resistant TB. The improved Tuberculosis
Control Program, which was implemented in 1992 with
aggressive case management and direct observation of anti-TB
therapy for most patients, quickly curtailed the development of
newly acquired drug resistance. Since primary and acquired
drug resistance and MDRTB, in particular, were prevalent
before 1995 (32,33), many MDRTB strains likely were dis-
seminated in the community because most patients in this
cohort with unique strains had no histories of prior treatment. 
In this study, we may have underestimated the number of
cases that had nosocomial and community epidemiologic
links. We did not use medical record reviews of hospitaliza-
tions before the diagnosis of MDRTB for all the patients to
identify potential nosocomial exposures. Many patients died
before identification of MDRTB; therefore, interviews could
not be conducted to identify potential nosocomial and commu-
nity exposures before diagnosis of TB. The outbreaks associ-
ated with the W and W1 strains were well investigated and
publicized, and staff were aware of the locations of the out-
break hospitals. This fact may have allowed for easier identifi-
cation of epidemiologic links in these patients. In the AB
community outbreak cluster, most epidemiologic links were
identified from the detailed interviews with the few patients
who were still alive. Traditional contact investigations did not
identify these links in this subpopulation. This observation
underscores that other methods, such as ongoing surveillance
for unusual patterns of disease and unusual patient characteris-
tics, should also be used to identify possible transmission in
the community.  Prospective DNA typing of all isolates can
also supplement traditional contact investigation methods.Emerging Infectious Diseases  •  Vol. 8, No. 11, November 2002 1237
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The molecular analysis of the MDRTB strains in New
York City during these years demonstrated that the improved
Tuberculosis Control Program has reduced dramatically the
transmission of these strains. These investigations have also
established important baseline data for the study of the epide-
miology of MDRTB over the next decades.
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